Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Q Ding, W Hu, R Wang, Q Yang, M Zhu, M Li… - Signal transduction and …, 2023 - nature.com
Rheumatoid arthritis (RA) is an incurable systemic autoimmune disease. Disease
progression leads to joint deformity and associated loss of function, which significantly …

Role of Bruton's tyrosine kinase in B cells and malignancies

S Pal Singh, F Dammeijer, RW Hendriks - Molecular cancer, 2018 - Springer
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

ANCA-associated vasculitis: an update

S Almaani, LA Fussner, S Brodsky, AS Meara… - Journal of clinical …, 2021 - mdpi.com
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group
of small vessel vasculitides characterized by granulomatous and neutrophilic tissue …

Pemphigus: current and future therapeutic strategies

D Didona, R Maglie, R Eming, M Hertl - Frontiers in immunology, 2019 - frontiersin.org
Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which
affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing …

LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells

AC Lino, V Lampropoulou, A Welle, J Joedicke… - Immunity, 2018 - cell.com
B lymphocytes can suppress immunity through interleukin (IL)-10 production in infectious,
autoimmune, and malignant diseases. Here, we have identified a natural plasma cell subset …

Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени

ЕЛ Насонов - Научно-практическая ревматология, 2017 - cyberleninka.ru
Ревматоидный артрит (РА) хроническое иммуновоспалительное (аутоиммунное)
заболевание, проявляющееся прогрессирующей деструкцией суставов, системным …

Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC‐0853) in systemic lupus erythematosus: results of a phase II …

D Isenberg, R Furie, NS Jones, P Guibord… - Arthritis & …, 2021 - Wiley Online Library
Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of
Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib …

The role of Bruton's tyrosine kinase in the immune system and disease

C McDonald, C Xanthopoulos, E Kostareli - Immunology, 2021 - Wiley Online Library
Bruton's tyrosine kinase (BTK) is a TEC kinase with a multifaceted role in B‐cell biology and
function, highlighted by its position as a critical component of the B‐cell receptor signalling …

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

C Liang, D Tian, X Ren, S Ding, M Jia, M **n… - European journal of …, 2018 - Elsevier
Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple
diseases, particularly haematopoietic malignancies and autoimmune diseases related to B …

Tyrosine kinases in autoimmune and inflammatory skin diseases

KP Szilveszter, T Németh, A Mócsai - Frontiers in immunology, 2019 - frontiersin.org
Tyrosine kinases relay signals from diverse leukocyte antigen receptors, innate immune
receptors, and cytokine receptors, and therefore mediate the recruitment and activation of …